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What is it? Fanconi anemia (FA) is
an autosomal recessive human
disease characterized by
congenital malformations, bone
marrow failure and cancer. FA
patients often develop leukemia
and/or squamous cell carcinomas
of the head and neck or
gynecologic system. FA cells are
hypersensitive to DNA crosslinking
agents, such as mitomycin C
(MMC) or diepoxybutane (DEB),
and the syndrome is believed to
result from a defect in DNA repair.
The genetics of FA? From
somatic cell fusion studies, FA has
at least eight complementation
groups. Seven FA genes have
been cloned, corresponding to
subtypes A, C, D1, D2, E, F and G.
Interestingly, the FANCD1 gene is
identical to the breast cancer
susceptibility gene BRCA2.
Biallelic disruption of any of these
seven FA genes results in the
common clinical and cellular
phenotype of FA patients.
FANCD2 is the only FA gene with
known homologues in
invertebrates (Drosophila and
Caenorhabditis elegans).
What is the function of the FA
genes? Perhaps not surprisingly,
the seven cloned FA proteins
interact in a common signaling
pathway (Figure 1). In a normal
human cell, five of the FA proteins
— A, C, E, F and G — form a
nuclear complex, required for the
monoubiquitination of the
downstream FANCD2 protein.
After cellular exposure to
genotoxic agents,
monoubiquitinated (activated)
FANCD2 is targeted to nuclear
foci which also contain BRCA1
and FANCD1/BRCA2.
Any related human syndromes?
Other human genetic diseases,
such as ataxia telangiectasia (AT)
and Nijmegen’s breakage
syndrome (NBS), also display
spontaneous chromosome
breakage and cancer
predisposition. Interestingly, the
ATM and NBS1 proteins interact
with elements of the FA/BRCA
pathway, perhaps accounting for
the partial overlap in these clinical
syndromes.
What does the FA/BRCA
pathway do? Recent evidence
indicates that biallelic mutations
of BRCA1 or BRCA2 in tumor
cells results in a defect in DNA
repair by homologous
recombination. The FA/BRCA
pathway appears to regulate
homologous recombination repair
during S phase or following DNA
damage by crosslinking agents,
although the precise function of
the downstream
monoubiquitinated FANCD2
protein in this process remains
unknown.
Relevance to cancer in the
general population? Like many
human cancers, FA cells display
chromosome instability and cis-
platinum sensitivity.  Recent
studies indicate that acquired
(somatic) disruption of the
FA/BRCA pathway can account
for these features in some
sporadic tumors in the general
population, such as ovarian and
breast cancer.  The FANCF gene,
for example, is methylated and
inactivated in approximately 20%
of epithelial ovarian cancers,
perhaps accounting for the cis-
platinum sensitivity of at least a
subset of these tumors.
Demethylation of FANCF and
reactivation of the FA/BRCA
pathway may result in the
emergence of drug-resistant
tumor cells.
Are FA genes also BRCA
genes? BRCA2+/– heterozygotes
have an increased risk of
developing breast, ovarian and
other cancers. As BRCA2 is an FA
gene, we speculate that
heterozygote carriers of mutations
in other FA genes — A, C, D2, E, F
and G — may also have an
increased cancer risk. The cancer
risk may depend on the FA
subtype or the presence of
specific mutant FA alleles.
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Figure 1. Interaction of the FA/BRCA pathway with ATM and NBS.
The FA complex — A/C/E/F/G — is required for the monoubiquitination of FANCD2
protein. ATM phosphorylates FANCD2. Activated FANCD2 is translocated to the chro-
matin where it interacts with BRCA1, BRCA2 and the NBS/Mre11 complex.
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